Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2019-A00987-50 | Other Identifier | ID RCB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate the feasibility of using a smartphone application for monitoring and evaluation of Raynaud's Phenomenon.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Raynaud phenomenon | Use of smartphone application |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Smartphone application | Other | use of smartphone application during 2 weeks to 3 months to collect frequency and duration of crises, RCS, photography of finger. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Satisfaction assessed by a 5-points Likert scales about using the application for the monitoring and evaluation of Raynaud's Phenomenon | The questionnaire assesses different items such as the ease of use of the application, the installation process on the smartphone, the use of reminders, etc. Overall satisfaction will be calculated as the non-weighted average of all items. | 2 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Relationship between cutaneous digital temperature assessed by thermography and the severity of Raynaud's Phenomenon | Correlation between digital temperature and Raynaud's Condition Score (RCS) | 2 weeks |
| Relationship between cutaneous digital temperature assessed by thermography and the frequency of RP attacks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients will be selected in conjunction with a scheduled consultation in the Vascular Medicine Department or at the Clinical Research Center
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Matthieu Roustit, PharmD, PhD | Contact | +33476767856 | mroustit@chu-grenoble.fr | |
| Adeline PARIS, PharmD, PhD | Contact | +33476767383 | aparis@chu-grenoble.fr |
| Name | Affiliation | Role |
|---|---|---|
| Matthieu Roustit, PharmD, PhD | University Hospital, Grenoble | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Chu Grenoble Alpes | Recruiting | Grenoble | Grenoble | 38043 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 27509103 | Background | Wigley FM, Flavahan NA. Raynaud's Phenomenon. N Engl J Med. 2016 Aug 11;375(6):556-65. doi: 10.1056/NEJMra1507638. No abstract available. | |
| 22782008 | Background | Herrick AL. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat Rev Rheumatol. 2012 Aug;8(8):469-79. doi: 10.1038/nrrheum.2012.96. Epub 2012 Jul 10. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011928 | Raynaud Disease |
| ID | Term |
|---|---|
| D000090122 | Livedoid Vasculopathy |
| D013927 | Thrombosis |
| D016769 | Embolism and Thrombosis |
| D014652 | Vascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Correlation between digital temperature and the daily frequency of attacks |
| 2 weeks |
| Relationship between cutaneous digital temperature assessed by thermography and the duration of RP attacks | Correlation between digital temperature and the cumulative daily duration of attacks | 2 weeks |
| Relationship between cutaneous digital temperature assessed by thermography and pain during RP attacks | Correlation between digital temperature and pain during attacks (assessed through a 10-point VAS) | 2 weeks |
| Effect of Raynaud etiology on thermographic data | Comparison of cutaneous digital temperature between patients with primary and secondary Raynaud | 2 weeks |
| Effect of Raynaud treatment on thermographic data | Comparison of cutaneous digital temperature between patients treated with calcium channel blockers and untreated patients | 2 weeks |
| 28859256 | Background | Seibold JR, Wigley FM. Editorial: Clinical Trials in Raynaud's Phenomenon: A Spoonful of Sugar (Pill) Makes the Medicine Go Down (in Flames). Arthritis Rheumatol. 2017 Dec;69(12):2256-2258. doi: 10.1002/art.40307. Epub 2017 Nov 10. No abstract available. |
| 30383134 | Background | Roustit M, Giai J, Gaget O, Khouri C, Mouhib M, Lotito A, Blaise S, Seinturier C, Subtil F, Paris A, Cracowski C, Imbert B, Carpentier P, Vohra S, Cracowski JL. On-Demand Sildenafil as a Treatment for Raynaud Phenomenon: A Series of n-of-1 Trials. Ann Intern Med. 2018 Nov 20;169(10):694-703. doi: 10.7326/M18-0517. Epub 2018 Oct 30. |
| 22275160 | Background | Fava A, Wung PK, Wigley FM, Hummers LK, Daya NR, Ghazarian SR, Boin F. Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon. Arthritis Care Res (Hoboken). 2012 Jun;64(6):925-9. doi: 10.1002/acr.21622. Epub 2012 Jan 24. |
| 29193819 | Background | Denton CP, Hachulla E, Riemekasten G, Schwarting A, Frenoux JM, Frey A, Le Brun FO, Herrick AL; Raynaud Study Investigators. Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study. Arthritis Rheumatol. 2017 Dec;69(12):2370-2379. doi: 10.1002/art.40242. |
| 8441170 | Background | Maricq HR, Carpentier PH, Weinrich MC, Keil JE, Franco A, Drouet P, Poncot OC, Maines MV. Geographic variation in the prevalence of Raynaud's phenomenon: Charleston, SC, USA, vs Tarentaise, Savoie, France. J Rheumatol. 1993 Jan;20(1):70-6. |
| D002318 |
| Cardiovascular Diseases |
| D016491 | Peripheral Vascular Diseases |
| D017445 | Skin Diseases, Vascular |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |